Friday, April 29, 2016

"Unless the masses start to demand economic freedom (and they don't have a clue about it now), this is exactly what lies ahead for America."
- Robert Wenzel, Austrian School Economist
(Photo from the cover of the 2011 book, United States of Banana, by Giannina Braschi. )


Anonymous said...

‘Clinton Cash’ Has Been Made Into a Movie
The Breitbart-funded broadside against Hillary Clinton will be screened in Cannes and have its U.S. premiere the week of the Democratic convention.

A year ago, before Donald Trump dubbed her “Crooked Hillary” and Bernie Sanders was assailing her secretive speeches to Wall Street banks, Hillary Clinton looked like a powerful presidential front-runner. Then, in May, HarperCollins published an investigative book about the Clintons by the conservative author Peter Schweizer that caught them off guard and took a prominent place in the political conversation for months. Clinton Cash: The Untold Story of How and Why Foreign Governments and Businesses Helped Make Bill and Hillary Rich became a surprise bestseller.

Today, Clinton has righted the ship and her candidacy looks stronger than ever. But while polls suggest Trump and Sanders will have a hard time stopping her, the team behind Clinton Cash—Schweizer and Stephen K. Bannon, the executive chairman of Breitbart News—haven’t given up. They’ve turned Clinton Cash into a movie, directed by M.A. Taylor, that will premiere next month in Cannes, France, during the Cannes Film Festival. (The movie is not a part of the festival, but will be shown at a screening arranged for distributors).

As the trailer below indicates, the Clinton Cash movie is less Ken Burns than Jerry Bruckheimer, featuring blood-drenched money, radical madrassas, and ominous footage of the Clintons:

Anonymous said...

Mental Dystrophy at the FDA
How the bureaucracy denies a new drug for a deadly disease.
April 28, 2016 7:19 p.m. ET

For anyone wondering why Americans disgusted with government would take a flyer on Donald Trump, consider Monday at the Food and Drug Administration: A panel of experts recommended denying young boys with a lethal form of muscular dystrophy access to an experimental drug with four years of promising clinical results.

A 13-member FDA advisory committee voted against approving eteplirsen, a treatment for Duchenne muscular dystrophy by Sarepta Therapeutics, concluding that there wasn’t sufficient evidence the drug was effective. Some 800 physicians, patients and parents beg to differ and showed up at the 11-hour hearing in Maryland. FDA can follow or ignore the committee and is set to decide by May 26.

Duchenne, a fatal genetic mutation typically found in boys, damages muscles and confines young men to wheelchairs before their heart or lungs fail. Most die before age 25. Eteplirsen jumps over deficient genetic code to produce a missing protein known as dystrophin. The drug is not a cure, but it slows the march toward death and on all the evidence so far improves the quality of their days on earth.

With no safety concerns, the worst result of approval is that FDA would set a precedent for smaller trials for innovative drugs for rare diseases. It’s a gross failure of government that this could outweigh the alternative: Funerals for the young men who came to Washington this week to beg for a longer shot at life.